Skip to content
BiologicalX

Comparison

Alpha-Lipoic Acid vs Ipamorelin

Side-by-side of Alpha-Lipoic Acid and Ipamorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-Lipoic Acid

  • Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
  • Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
  • R-ALA enantiomer absorbs 40-100% better than racemic mixtures
  • Activates AMPK; produces small HbA1c reductions in T2DM
  • Plasma half-life ~30 minutes; split dosing or sustained-release is standard
  • Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required

Ipamorelin

  • Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
  • Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
  • ~2 hour plasma half-life, longest of the synthetic GHRPs
  • Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
  • Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
  • Banned by WADA under S2; never reached registration despite phase 2b development

Side-by-side

Attribute Alpha-Lipoic Acid Ipamorelin
Category supplement peptide
Also known as ALA, thioctic acid, R-ALA, R-lipoic acid NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2
Half-life (hr) 0.5 2
Typical dose (mg) 600 0.2
Dosing frequency 1 to 3 times daily on empty stomach 2-3x daily
Routes oral, iv subcutaneous, intravenous
Onset (hr) 0.5 0.25
Peak (hr) 1 1
Molecular weight 206.33 711.86
Molecular formula C8H14O2S2 C38H49N9O5
Mechanism Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs.
Legal status Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA
WADA status allowed banned
DEA / Rx Not scheduled Not scheduled (research chemical)
Pregnancy Insufficient data; precautionary avoidance Insufficient data; not recommended
CAS 62-46-4 170851-70-4
PubChem CID 864 11338566
Wikidata Q161227 Q1666741

Safety profile

Alpha-Lipoic Acid

Common side effects

  • nausea
  • abdominal discomfort
  • diarrhea
  • sulfurous odor
  • rash (rare)

Contraindications

  • pregnancy and lactation (insufficient safety data)
  • active insulin autoimmune syndrome predisposition

Interactions

  • insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
  • thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
  • biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
  • iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
  • chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)

Ipamorelin

Common side effects

  • injection-site irritation
  • vivid dreams
  • transient mild head pressure
  • occasional headache

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes

Interactions

  • CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
  • sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response; reduce expected efficacy(moderate)

Which Should You Take?

Alpha-Lipoic Acid comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.

  • If your priority is metabolic health and glucose control, pick Alpha-Lipoic Acid.
  • If your priority is healthspan extension, pick Alpha-Lipoic Acid.
  • If your priority is growth-hormone axis, pick Ipamorelin.
  • If your priority is post-training recovery, pick Ipamorelin.

Edge case: If you want to avoid research-only / gray-market sourcing, Alpha-Lipoic Acid is the more accessible choice.

Default choice: Alpha-Lipoic Acid. Lower friction to source, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-Lipoic Acid and Ipamorelin?

Alpha-Lipoic Acid and Ipamorelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-Lipoic Acid or Ipamorelin?

Alpha-Lipoic Acid half-life is 0.5 hours; Ipamorelin half-life is 2 hours.

Can you stack Alpha-Lipoic Acid with Ipamorelin?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper